The learning framework
The founder who owned sixty percent
An inventor spins out a company around a medical device. The university receives equity in the new company and retains economic rights under the IP license. At formation, the inventor owns sixty percent. It feels substantial. More substantial, certainly, than the royalty percentage available through a licensing path. Then the company begins building what commercialization requires. An employee option pool is created. Outside capital comes in. Additional financing is needed to reach development, clinical, regulatory, and commercial milestones. Each financing changes the ownership structure, and the founder's percentage continues to fall. Years later, the founder owns a single-digit percentage of the company. The licensing path rejected at the beginning might have produced royalties, milestones, or other payments without requiring the inventor to finance and operate a company. That does not mean licensing would have been better. It does not mean spinning out was wrong. The problem is that the two paths were never actually compared. Sixty percent of a company at formation and a royalty on future sales are not competing numbers. They are different claims on different outcomes, exposed to different risks over different periods of time. The Fork begins by putting them into the same decision.
The question comes before the calculation
The first question is not whether you can form a company around the innovation. It is whether the innovation justifies one. A standalone healthcare company may need capital, regulatory capability, clinical development, quality systems, manufacturing, reimbursement strategy, distribution, sales, customer support, complementary technology, and an organization capable of coordinating them. An established company may already possess many of those capabilities. That can make an innovation highly valuable to an existing company while making it a poor foundation for a new one. The opposite can also be true. An innovation may create enough differentiated value, strategic control, market opportunity, and expansion potential to justify building the missing capabilities around it. Only then does the economic comparison become useful. Licensing and spinout economics are expressed differently. A license may involve upfront payments, milestones, royalties, minimum payments, sublicensing participation, diligence obligations, and other commercial terms. A spinout involves equity that may be affected by institutional ownership, option pools, capital requirements, financing rounds, dilution, and investor rights. The purpose of the comparison is not to predict either outcome perfectly. It is to expose the assumptions hidden inside the choice.
A path chosen rather than defaulted into
Healthcare innovators who complete this evolution do not treat company formation as the natural reward for inventing something valuable. They determine whether the opportunity can support a company, identify which commercialization structure is better positioned to move it forward, and compare the economics of the available paths under common assumptions. They can read the terms behind a licensing offer and recognize which provisions materially change its value. They understand how ownership, capital requirements, dilution, development burden, regulatory demands, institutional economics, commercial infrastructure, and founder responsibility affect the alternative of building a company. They can explain why they chose to license, spin out, or stop. And they identify in advance what evidence would cause them to change that decision. Walking away is therefore not treated as failure. It is treated as one of the available commercialization decisions, made before sunk cost, identity, or years of effort make it difficult to choose.
By the end of this evolution, you will be able to:
Determine whether an innovation supports a standalone company
Distinguish between a technology that has commercial value and an opportunity capable of supporting an entire company. Evaluate whether the market, strategic position, capital requirements, infrastructure, development burden, and potential for continued value creation justify building an organization around the innovation.
Compare licensing and spinout as commercialization structures
Evaluate what an existing organization can already provide and what a new company would have to build. Compare strategic focus, control, regulatory capability, manufacturing, reimbursement, distribution, commercial infrastructure, complementary assets, and access to capital across the two paths.
Model licensing and spinout economics in comparable terms
Translate royalties, milestones, sublicensing economics, founder equity, dilution, financing requirements, and potential exit proceeds into a common decision framework. Understand why a percentage of sales and a percentage of company ownership cannot be compared directly.
Read the terms behind a licensing offer
Work through provisions that can materially affect commercialization economics and control, including upfront payments, milestones, running royalties and their base, minimum payments, sublicensing income, diligence obligations, patent expenses, exclusivity, field and territory restrictions, and termination rights. For institution-owned innovations, understand how these provisions commonly appear in a university license term sheet.
Understand what the institution and inventor receive
Distinguish institutional ownership from inventor economics. Understand how licensing rights, institutional equity, royalties, inventor-sharing policies, and other obligations may interact rather than assuming that equity replaces royalty economics or that every institution structures spinouts the same way.
Understand what your technology transfer office can and cannot do
Learn which terms an office has discretion over and which are fixed by institutional policy or by federal obligation. Understand the constraints the office operates under so that your requests are ones it is able to act on.
Incorporate development and regulatory burden into the decision
Understand how different healthcare development pathways influence capital requirements, timing, execution risk, financing needs, and potential dilution. Recognize why those requirements may make an existing commercialization platform more attractive for one innovation while supporting a new company around another.
Evaluate spinout and venture-building structures
Assess founder-led companies, university spinouts, incubators, venture studios, and other company-building models based on what they provide, what ownership or control they require in exchange, and what capabilities or capital would otherwise have to be assembled independently. Evaluate the economics that affect the commercialization choice without treating company formation as a substitute for a full financing strategy.
Recognize when walking away is the right answer
Identify conditions under which neither licensing nor company formation creates an acceptable commercial opportunity. Establish thresholds around market potential, development burden, required capital, commercial economics, structural obligations, and opportunity cost before emotional or financial commitment makes stopping more difficult.
Why this matters
Recommended for
Healthcare innovators navigating:
Faculty who understand the process move through it faster.
Academic medical centers, research universities, and health systems sponsor cohorts so that inventors arrive at the office of technology transfer prepared: complete disclosures, clean assignment records, and realistic expectations about pathway and timeline. Cohort training is available for faculty, residents, and research staff, with CME.
Learn more about institutional cohorts →How to get started
Your path to becoming a Certified Professional Entrepreneur
Reserve your seat
Your deposit reserves a place in the cohort. Twenty seats. No application, no admissions committee, no waiting on a decision.
Begin the evolutions
Structured online learning you work through on your own schedule. Lectures run under fifteen minutes. Each evolution carries reading, supporting material, working tools, and case studies drawn from real transactions.
Join the live sessions
Live discussion sessions on Zoom, facilitated by Chris and Christos. Not recorded. This is where the material meets your actual situation, and where the cohort becomes a network.
Continue your structural training
Answers that help you decide with confidence
Most inventors choose a path before they have modeled what it pays them.